Evidence map›Paper›PMID 40863989›Full record

ReviewNeurology international2025

The Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge.

Mengjiao Xu, Zhiyu Zhang, Zhoudong Zhang, Dong Liu, Yanguo Shang, Chenglun Tang, Weipeng Wang, Huanqiu Li, Bengang You, Hanjie Ying and 1 more

Abstract readReview
In one paragraph

Review in Neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengjiao XuCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.ORCID 0000-0002-2842-3115
Zhiyu ZhangCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
Zhoudong ZhangCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.ORCID 0000-0001-5928-8828
Dong LiuCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.ORCID 0000-0002-3009-7590
Yanguo ShangCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
Chenglun TangJiangsu Institute of Industrial Biotechnology, JITRI Co., Ltd., Nanjing 210000, China.
Weipeng WangCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
Huanqiu LiCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
Bengang YouCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
Hanjie YingCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
Tao ShenCollege of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.

Funding

National Key Research and Development Program of China 2024YFA0917800the Program of National Natural Science Foundation of China No.22208155
6 · The paper itself

Abstract

Depression is a common mental disorder with high economic burden, characterized by high disability and mortality rates. The etiology of depression remains unclear to date, and there are various hypotheses regarding the pathogenesis of depression in clinical practice, including the monoamine neurotransmitter hypothesis, the hypothalamic-pituitary-adrenal (HPA) axis dysregulation hypothesis, the inflammatory cytokine hypothesis, and the neurotrophic factor hypothesis. These theories offer specific directional aid in the clinical management of individuals suffering from depression. Medicinal intervention stands as a critical approach within the spectrum of depression treatments, and this article reviews the specific mechanisms of different hypotheses on the pathogenesis of depression in recent years, as well as the research progress on related therapeutic drugs.

Indexed as

depressiongut–brain axisHPAinflammatory factorsserotonintherapeutic drugs

Identifiers

PMID40863989
PMCPMC12388545

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.